Brief: Genfit Q1 Cash Position EUR 108.9 Mln

Genfit SA

15/06/2021 13:53

June 15 (Reuters) - GENFIT SA  GNFT.PA :
    * LEAD PROGRAM IN PBC THERAPEUTICS: TOPLINE DATA READOUT
EXPECTED
IN 1Q23 AND NEXT CORPORATE UPDATE IN SEPT 2021
    * LEAD PROGRAM IN NASH DIAGNOSTICS: NEXT CORPORATE UPDATE IN
SEPT
2021
    * FINANCES: 1Q21 CASH POSITION: €108.9M
    * FINANCES: ON TRACK TO ACHIEVE AROUND €45M OPERATIONAL
CASHBURN
IN 2022
    * FINANCES: CONVERTIBLE DEBT MATURITY PUSHED BACK TO OCT
2025
    * FINANCES: RESIDUAL CONVERTIBLE DEBT DOWN TO NOMINAL AMOUNT
OF
€57.2M AS OF APRIL 13, 2021
    * RATIONALE: NEW CLINICAL EVIDENCE EXPECTED IN CHOLESTATIC
DISEASES, WITH PSC DATA IN 2022 (ELAFIBRANOR)
    * RATIONALE IN ACLF: FIRST CLINICAL EVIDENCE EXPECTED IN
2022
(NTZ)

Source text for Eikon:  ID:nNDL3ZZNx4 
Further company coverage:  GNFT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))